Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant has a diagnosis of Alzheimer's Disease (AD) and is prescribed aducanumab-avwa by their treating physician.
Participant's treating physician has made the decision to initiate aducanumab-avwa prior to participant inclusion and independently of the purpose of the study.
You may not be if
Participant concurrently participates in any interventional clinical study.
Participant has ever been treated with aducanumab-avwa at a dose of 3 milligrams per kilogram (mg/kg) or greater prior to signing ICF.
Participant has ever been treated with aducanumab-avwa and discontinued treatment prior to signing ICF.
Clareo Health | An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
